ribavirin

Janssen privy to new pricing scheme and see NICE nod

Janssen’s hepatitis C drug Olysio has been approved by NICE whilst also reaching a novel ‘pay if you clear’ pricing agreement with the NHS.

The payment scheme means that NHS England will only pay for Olysio (simeprevir) if patients are effectively cured of the virus after 12 weeks of treatment, with Janssen refunding the cost for those who aren’t. Trials so far have found a cure rate of around 80% after 12 weeks of using the drug.

Valeant recalls drug used on hospitalised infants

The company has faced a series of setbacks over the last few months

North American drug firm Valeant Pharmaceuticals has issued a voluntary nationwide recall of Virazole due to microbial contamination.

Virazole (ribavirin powder for solution) is indicated for the treatment of hospitalised infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus.

Mission Statement

Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,

Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches